Severe Hypovitaminosis D Correlates with Increased Inflammatory Markers in HIV Infected Patients

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2013 Jan 9

PMID 23295013

Citations 16

Authors

Thiphaine Ansemant

Sophie Mahy

Christine Piroth

Paul Ornetti

Stephanie Ewing

Jean-Claude Guilland

Delphine Croisier

Laurence Duvillard

Pascal Chavanet

Jean-Francis Maillefert

Lionel Piroth

Affiliations

Soon will be listed here.

Abstract

Background: Even though it has been suggested that antiretroviral therapy has an impact on severe hypovitaminosis D (SHD) in HIV infected patients, it could be speculated that the different levels of residual inflammation on HAART (Highly Active Anti Retroviral Therapy) could contribute to SHD and aggravate bone catabolism in these patients.

Methods: A cross-sectional study was carried out in an unselected cohort of 263 HIV infected outpatients consulting during Spring 2010. Clinical examinations were performed and medical history, food habits, sun exposure and addictions were collected. Fasting blood samples were taken for immunological, virological, inflammation, endocrine and bone markers evaluations.

Results: Ninety-five (36%) patients had SHD. In univariate analysis, a significant and positive association was found between SHD and IL6 (p = 0.001), hsCRP (p = 0.04), increased serum C-Telopeptides X (CTX) (p = 0.005) and Parathyroid Hormon (PTH) (p < 0.0001) levels. In multivariate analysis, SHD deficiency correlated significantly with increased IL-6, high serum CTX levels, lower mean daily exposure to the sun, current or past smoking, hepatitis C, and functional status (falls), but not with the time spent on the current HAART (by specific drug or overall).

Conclusions: SHD is frequent and correlates with inflammation in HIV infected patients. Since SHD is also associated with falls and increased bone catabolism, it may be of interest to take into account not only the type of antiretroviral therapy but also the residual inflammation on HAART in order to assess functional and bone risks. This finding also suggests that vitamin D supplementation may be beneficial in these HIV-infected patients.

Citing Articles

Subtrochanteric Pathological Femur Fracture in an HIV-Positive Patient on Tenofovir-based antiretroviral therapy: A Case Report and Review of the Literature.

Choudhary S, Rangasamy K, Naidu S, Sachdeva R, Sharma A J Orthop Case Rep. 2023; 13(2):14-20.

PMID: 37144071 PMC: 10152932. DOI: 10.13107/jocr.2023.v13.i02.3538.

Hypovitaminosis D Is Associated with Higher Levels of Inflammatory Cytokines and with HAM/TSP in HTLV-Infected Patients.

Netto E, Silva A, Pedroso C, Brites C Viruses. 2021; 13(11).

PMID: 34835029 PMC: 8623239. DOI: 10.3390/v13112223.

The Potential Protective Role of Vitamin D Supplementation on HIV-1 Infection.

Alvarez N, Aguilar-Jimenez W, Rugeles M Front Immunol. 2019; 10:2291.

PMID: 31611877 PMC: 6773828. DOI: 10.3389/fimmu.2019.02291.

Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1.

Missailidis C, Sorensen N, Ashenafi S, Amogne W, Kassa E, Bekele A Nutrients. 2019; 11(7).

PMID: 31330899 PMC: 6682943. DOI: 10.3390/nu11071675.

The impact of vitamin D supplementation on musculoskeletal health outcomes in children, adolescents, and young adults living with HIV: A systematic review.

Penner J, Ferrand R, Richards C, Ward K, Burns J, Gregson C PLoS One. 2018; 13(11):e0207022.

PMID: 30439968 PMC: 6237309. DOI: 10.1371/journal.pone.0207022.

References

Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane H . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203. PMC: 2570418. DOI: 10.1371/journal.pmed.0050203. View

Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala N . Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas. 2009; 65(3):225-36. DOI: 10.1016/j.maturitas.2009.12.013. View

Piso R, Rothen M, Rothen J, Stahl M . Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr. 2011; 56(4):320-4. DOI: 10.1097/QAI.0b013e31820cf010. View

Guillot X, Semerano L, Saidenberg-Kermanach N, Falgarone G, Boissier M . Vitamin D and inflammation. Joint Bone Spine. 2010; 77(6):552-7. DOI: 10.1016/j.jbspin.2010.09.018. View

George J, Ganesh H, Acharya S, Bandgar T, Shivane V, Karvat A . Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol. 2009; 15(28):3516-22. PMC: 2715978. DOI: 10.3748/wjg.15.3516. View

Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F . HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009; 23(8):929-39. DOI: 10.1097/qad.0b013e32832995fa. View

Fardellone P, Sebert J, Bouraya M, Bonidan O, Leclercq G, Doutrellot C . [Evaluation of the calcium content of diet by frequential self-questionnaire]. Rev Rhum Mal Osteoartic. 1991; 58(2):99-103. View

Van Den Bout-Van Den Beukel C, Fievez L, Michels M, Sweep F, Hermus A, Bosch M . Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008; 24(11):1375-82. DOI: 10.1089/aid.2008.0058. View

Dao C, Patel P, Overton E, Rhame F, Pals S, Johnson C . Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011; 52(3):396-405. DOI: 10.1093/cid/ciq158. View

10.

Libois A, Clumeck N, Kabeya K, Gerard M, de Wit S, Poll B . Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas. 2009; 65(1):51-4. DOI: 10.1016/j.maturitas.2009.10.009. View

11.

Viard J, Souberbielle J, Kirk O, Reekie J, Knysz B, Losso M . Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011; 25(10):1305-15. DOI: 10.1097/QAD.0b013e328347f6f7. View

12.

Bischoff-Ferrari H, Dawson-Hughes B, Willett W, Staehelin H, Bazemore M, Zee R . Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004; 291(16):1999-2006. DOI: 10.1001/jama.291.16.1999. View

13.

Rodriguez M, Daniels B, Gunawardene S, Robbins G . High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2008; 25(1):9-14. DOI: 10.1089/aid.2008.0183. View

14.

Wasserman P, Rubin D . Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS. 2010; 24(4):223-7. DOI: 10.1089/apc.2009.0241. View

15.

Overton E, Yin M . The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations. Curr Infect Dis Rep. 2011; 13(1):83-93. DOI: 10.1007/s11908-010-0144-x. View

16.

McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Tebas P . Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy.... J Infect Dis. 2011; 203(12):1791-801. PMC: 3100514. DOI: 10.1093/infdis/jir188. View

17.

Mueller N, Fux C, Ledergerber B, Elzi L, Schmid P, Dang T . High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010; 24(8):1127-34. DOI: 10.1097/QAD.0b013e328337b161. View

18.

Vescini F, Cozzi-Lepri A, Borderi M, Re M, Maggiolo F, De Luca A . Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011; 58(2):163-72. DOI: 10.1097/QAI.0b013e31822e57e9. View

19.

Bellia A, Garcovich C, DAdamo M, Lombardo M, Tesauro M, Donadel G . Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med. 2011; 8(1):33-40. DOI: 10.1007/s11739-011-0559-x. View

20.

Lau B, Sharrett A, Kingsley L, Post W, Palella F, Visscher B . C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006; 166(1):64-70. DOI: 10.1001/archinte.166.1.64. View